ClinicalTrials.gg
CompletedNCT03997734Updated Mar 30, 2020

Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

A Phase 1 interventional study of AB001 and oral capsule in Chronic Low Back Pain, sponsored by Frontier Biotechnologies Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Frontier Biotechnologies Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Low Back Pain with a site in China — 17 open to participants now, 19 under way, none of them phase 3. Low Back Pain · China.

Enrollment
36th of 42
34 · median 84
Started
2019
with 2 others
Phase 1
2 of 49
1 open now
Registered
13th of 49
by date

Among the 49 studies in Low Back Pain with a site in China, this one is the 36th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 13th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

17 of the 49 studies in Low Back Pain with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Low Back Pain with a site in China, or all of them as a file.
02

Study summary

The study evaluates the safety, tolerability and pharmacokinetics of single and repeated doses of topical AB001 patch and the bioavailability relative to the oral capsule and topical positive comparative patch.

Read the detailed description

Eligible subjects will be randomly assigned to Treatment goup A, B and C.

In the experiment group A, 12 subjects with a ratio of 10:2 will receive one patch of AB001 or placebo batch on Day 1 of period 1, respectively, after a wash-out period of 14 days, 10 subjects received AB001 patch will be administered with an oral capsule of active ingredient on Day 20 of period 2.

In the experiment group B, 12 subjects with a ratio of 10:2 will receive two patches of AB001 or two placebo batches on Day 1 respectively, and then two patches daily from Day 8 to Day 20.

In the active comparator group C, 10 subjects will receive one patch of positive comparative patch on Day 1, and then once patch every two days from Day 8 to Day 20.

The tolerability, safety and pharmacokinetics of topical AB001 patch will be assessed in this study.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects between 18 and 45 years with a of 18 to 30 kg/m2, inclusive, and weigh at least 45 kg.
  2. Subjects having normal skin without excessive hair growth on tested areas.
  3. Evidence of a personally signed and dated document indicating that the subjects has been informed of all pertinent aspects of the trial.
  4. Subjects who are willing to comply with scheduled visits and other trial procedures

Exclusion criteria

Exclusion Criteria:

  1. A history or presence of significant cardiovascular, neurological, hematological, psychiatric, infectious, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease or other conditions known to interfere with the topical absorption, distribution, metabolism, or excretion of drugs or place the subjects at increased risk as determined by the investigator
  2. History of to NSAIDs
  3. laboratory abnormalities as judged by the investigator
  4. Known sensitivity to adhesive tape, component of the test products or topically applied products
  5. Any active
  6. Suffering from severe acne, moderate to severe hirsutism or androgenic alopecia
  7. Any chronic skin disorder (e.g., eczema, psoriasis) likely to interfere with transdermal drug absorption or assessment of skin tolerability
  8. Skin abnormalities likely to be aggravated by the study medication, such as dermatological diseases or infections, rash, skin sensitive to topical preparations or adhesive dressings
  9. Pregnant and/or nursing women
  10. Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the investigator, would interfere with the outcome of the trial
  11. History of alcohol or drug abuse within 18 months
  12. Blood donation or significant blood loss within 60 days of dosing or plasma donation within 7 days of dosing
  13. Use of any medication within 4 weeks prior to the first treatment or during the trial, which in the opinion of the investigator may influence the trial results or the safety of the subjects
  14. Subjects who cannot avoid, throughout the duration of the trial, any swimming, any washing of the back, and sauna or any intense physical activity that might result in excessive sweating
  15. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Treatment A-AB001

    Apply 1 patch of AB001 patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1. Subjects who received the AB001 patch in period 1 will then receive a single oral capsule of active ingredient on Day 20 in period 2.

    Drug: AB001 · Drug: oral capsule

  • Experimental
    Treatment B-AB001

    Apply 2 patches of AB001 patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.

    Drug: AB001

  • Active comparator
    Treatment C

    Apply 1 patch of positive comparative patch on the lower back of the subjects on either side of the spine without occlusion for 48 hours on Day 1 and then one patch every two days from Days 8 to 20.

    Drug: positive comparative patch

  • Placebo comparator
    Treatment A-Placebo

    Apply 1 patch of placebo patch on the lower back of the subjects on either side of the spine without occlusion for 12 hours on Day 1 in period 1.

    Drug: Placebos

  • Placebo comparator
    Treatment B-Placebo

    Apply 2 patches of placebo patches on the lower back of the subjects on side of the spine without occlusion for 12 hours on Day 1 and then once daily from Day 8 to 20.

    Drug: Placebos

Interventions

  • DrugAB001

    single and repeated dosing

    Also known as: topical patch

  • Drugoral capsule

    single dose

    Also known as: active ingredient

  • Drugpositive comparative patch

    single and repeated dosing

    Also known as: topical patch

  • DrugPlacebos

    single and repeated dosing

    Also known as: topical patch

06

What researchers measure

Primary outcomes

  1. Number of subjects with any adverse events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From baseline through Day 26

  2. Number of subjects any serious adverse events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect.

    Time frame: From baseline through Day 26

Secondary outcomes

  1. Safety Assessments on Skin Reaction Evaluation

    Topical Skin Reaction Score(0-2 is a better outcome): 0= no evidence of irritation 1. minimal erythema, barely perceptible 2. definite erythema, readily visible; minimal edema or minimal papular response 3. erythema and papules 4. definite edema 5. erythema, edema and papules 6. vesicular eruption 7. strong reaction spreading beyond application site

    Time frame: From baseline through Day 26

  2. pharmacokinetic parameters of AB001(Cmax)

    Peak Plasma Concentration (Cmax)

    Time frame: Day 1 and Day 26

  3. pharmacokinetic parameters of AB001 (AUC)

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Day 1 and Day 26

  4. bioavailability of AB001

    To determine the bioavailability of AB001

    Time frame: Day 1 and Day 26

07

Study locations

1 site
  • The Third People's Hospital of Wuxi
    Wuxi, Jiangsu 214041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Nov 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2019
First posted
Jun 25, 2019
StartActual
Jun 24, 2019
Primary completionActual
Nov 11, 2019
CompletionActual
Nov 11, 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03997734
Lead sponsor
Frontier Biotechnologies Inc.
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Jun 24, 2019
Primary completion
Nov 11, 2019
Completion
Nov 11, 2019
Last update
Mar 30, 2020

Study contacts

Frontier clinical team
study director · Frontier Biotechnologies Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AB-001

Start the discussion